Table 1.
Basic clinical features of 12 literature were included in our study.
| Study | Age | Gender (man) | Disease types | Experimental group (N) | Control group (N) | NOS score | Research type |
|---|---|---|---|---|---|---|---|
| Borgheresi A 2020 | 53.71 ± 12.2 | 41.25 | Advanced liver cancer | 98 | 70 | 8 | RCT |
| Görgec B 2020 | 65.65 ± 13.4 | 69.12 | Advanced liver cancer | 88 | 60 | 7 | RCT |
| Yamada R 2019 | 53.12 ± 14.5 | 45.72 | Advanced liver cancer | 120 | 110 | 8 | RCT |
| Van Rosmalen 2019 | 67.15 ± 14.5 | 44.12 | Advanced liver cancer | 68 | 60 | 8 | RCT |
| Nurili F 2021 | 52.85 ± 11.4 | 51.89 | Advanced liver cancer | 60 | 75 | 8 | RCT |
| Newgard BJ 2019 | 64.36 ± 10.2 | 63.45 | Advanced liver cancer | 56 | 67 | 7 | RCT |
| Yarmohammadi 2018 | 62.62 ± 12.2 | 78.10 | Advanced liver cancer | 80 | 77 | 9 | RCT |
| Kouri BE 2018 | 62.61 ± 13.0 | 48.75 | Advanced liver cancer | 81 | 60 | 9 | RCT |
| Lewis AL 2018 | 57.25 ± 14.5 | 59.23 | Advanced liver cancer | 43 | 58 | 7 | RCT |
| Ronald J 2018 | 66.22 ± 15.2 | 56.22 | Advanced liver cancer | 60 | 72 | 8 | RCT |
| Furumaya A 2019 | 71.35 ± 11.1 | 53.16 | Advanced liver cancer | 110 | 102 | 8 | RCT |
| Franken LC 2020 | 57.25 ± 16.0 | 66.34 | Advanced liver cancer | 90 | 79 | 8 | RCT |